The functional diversity of the tumor suppressor protein p53 is mainly regulated by protein interactions. In this study, we describe a new interaction with the peptidylprolyl cis/trans isomerase cyclophilin 18 (Cyp18). The interaction reduced the sequence-specific DNA binding of p53 in vitro, whereas the inhibition of the interaction increased p53-reporter gene activity in vivo. The active site of the folding helper enzyme Cyp18 was directly involved in binding. The proline-rich region (amino acids 64-91) of p53 was most likely responsible for the observed binding because a synthetic peptide comprising amino acids 68-81 of p53 inhibited this interaction, and a p53 variant containing a proline residue at position 72 (p53 P72 ) interacted with Cyp18 more effectively than the corresponding p53 R72 variant. Impairment of the Cyp18-p53 interaction induced an accumulation of cells in the G2/M phase of the cell cycle, which was more pronounced when p53 P72 was expressed compared with p53 R72 in an otherwise isogenic cellular background. Moreover, p53-dependent apoptosis was elevated in Cyp18 knockout cells, suggesting an antiapoptotic potential of Cyp18-p53 complexes. Functional in vivo data hint to a possible clinical relevance of the p53-Cyp18 interaction observed.
Introduction
The tumor suppressor p53 represents a transcription factor constituting a hub within a network that guarantees a fine-tuned cellular response to several stress stimuli. The tumor suppressor initiates up-or downregulation of numerous target genes, with the respective gene products involved in a manifold of downstream pathways. The most intensively studied pathways are self-regulation of the intracellular levels of p53 by sequestration and proteolysis, cell-cycle control, DNA repair and recombination, and, last but not least, apoptosis and cellular senescence (for reviews, see, for example, Vogelstein et al., 2000; Laptenko and Prives, 2006; Vousden and Lane, 2007) . In many cases, it remains to be clarified how the various transcriptional responses to different stimuli are generated. Most likely, posttranslational modifications and protein-protein interactions are involved in driving p53 into a specific functional pathway. A plethora of interacting proteins are known suggesting that p53 is able to nucleate large protein complexes in vivo (see, for example, http:// dip.doe-mbi.ucla.edu/dip).
Several folding helper proteins were shown to interact with p53, such as the chaperones hsp90 (Scheibel and Buchner, 1998; Whitesell et al., 1998; King et al., 2001) , hsp70 (Akakura et al., 2001; Zylicz et al., 2001 ) and the peptidyl prolyl cis/trans isomerase (PPIase) Pin1 Zacchi et al., 2002; Zheng et al., 2002) . PPIases are enzymes that catalyse cis/trans isomerizations of peptide bonds N-terminal to proline residues (Fischer et al., 1989) . The enzymatic activity of Pin1 depends on the phosphorylation status of threonines or serines followed by a proline residue (Yaffe et al., 1997) . After DNA damage, Pin1 interacts with phosphorylated p53 and specifically catalyses the cis/trans isomerization of the Thr81(PO 3 H 2 )-Pro82 bond in p53. Pin1 was found to modulate cellular pathways such as cell cycle regulation (see, for example, Fujimori et al., 1999; Liou et al., 2002) , tumor development (Rippmann et al., 2000; Wulf et al., 2003) , general transcription and splicing (Liu et al., 2001) , and signal transduction through different pathways (Hsu et al., 2001; Pinton et al., 2007) . In particular, Pin1 regulates the stability of p53, and thereby gives rise to cell cycle arrest by upregulation of the cyclin/CDK inhibitor p21 WAF/CIP1 . As several proteins, such as the transcription factor YY1 (Yang et al., 1995) or the Sin3-Rpd3 histone deacetylase (Are´valo-Rodrı´guez et al., 2000) , were found to be targeted by more than one PPIase, we aimed to analyse whether another PPIase besides Pin1 may also regulate p53.
In a recently performed unbiased mass spectrometry (MS) analysis of p53-protein complexes another PPIase cyclophilin 18 (Cyp18) was found to be one of the potential interaction partners of p53 (N Baum, unpublished data) . In this study, we confirmed our proteomic data by biochemical and cell biological means. Collectively, the data show that Cyp18 is a further member of the enzyme class of PPIases involved in p53 regulation in unstressed and stressed cells.
Results

Physical association of p53 with Cyp18
Cytoplasmic and nuclear protein fractions of CCRF-CEM cells were subjected to coimmunoprecipitation (CoIP) analysis using the anti-p53 antibody DO1. To remove unspecifically bound proteins, the Protein ASepharose beads were extensively washed. The remaining proteins were eluted and resolved by 12.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (Figure 1a ). Selected gel sections were subjected to LC-ESI-MS/MS for protein identification.
In total, some 200 potential interaction partners of p53 were found (N Baum, unpublished data), 14 of which represented folding helper proteins (see Supplementary  Table 1) . Two of those, namely Cyp18 and Cyp23, belong to the cyclophilin family of PPIases. As Cyp18 was preferably found in the cytoplasm and the nucleus (Marks et al., 1991) whereas Cyp23 resides in the endoplasmic reticulum (Price et al., 1994) , we focused our further analysis on potential Cyp18-p53 interactions. CoIP experiments revealed a Cyp18 association with p53 in both the cytoplasmic and nuclear fractions as shown by LC-ESI-MS/MS analysis ( Figure 1a , sections a and b). Indeed, Cyp18 could be detected by MS in gel sections that contained no apparent Coomassie-stained protein bands (Figure 2 in the Supplementary information). As a control, lysates from p53-free HL60 cells were subjected to CoIPs and subsequent LC-ESI-MS/MS. Only a few other proteins, but not Cyp18, could be detected in the controls (Figure 1a , sections c and d).
To confirm the association between Cyp18 and p53, the interaction was further analysed using different cell types. CoIPs with anti-p53 antibodies were performed using cytoplasmic and nuclear fractions from the T-lymphoblastic cell line CCRF-CEM, from the human breast cancer-derived MCF-7 cells, and from mouse embryonal fibroblasts. Wild-type p53 was expressed in Figure 1 Identification of cyclophilin 18 (Cyp18)-p53 interaction by mass spectrometry (MS) analysis and immunoblotting. (a) Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of p53-containing protein complexes precipitated from cytoplasmic (cyt) and nuclear (nuc) extracts of CCRF-CEM cells using the anti-p53 monoclonal antibody DO1. The p53-null HL-60 cell line was used as a negative control. Protein samples were applied to a 12.5% SDS-PAGE and subsequently stained with Coomassie. Sections a and b indicate areas in which Cyp18 was detected by MS. The Cyp18 peptides identified by LC-ESI-MS/MS are shown below; sections c and d were devoid of Cyp18. (b) Immunoblot detecting p53 and Cyp18 in cyt and nuc fractions from CCRF-CEM, MCF-7 and mouse embryonal fibroblast (MEF) cell lysates using the anti-p53 antibody DO1, the anti-mouse p53 Ab-7 or a polyclonal anti-Cyp18 antiserum (input control). (c) Immunoblot of subcellular extracts subjected to coimmunoprecipitation (CoIP) using the anti-p53 antibody DO1 and the anti-mouse p53 antibody Ab-3. The protein complexes were analysed by immunoblotting, with subsequent detection of p53 and Cyp18.
Cyclophilin 18-p53 interactions N Baum et al MCF-7 cells and in mouse embryonal fibroblasts, whereas mutant p53 (R175H/R248Q) was expressed in CCRF-CEM cells. According to the input controls performed by immunoblot analysis, p53 and Cyp18 were present in both the nuclear and cytosolic fractions (Figure 1b) . After performing CoIP experiments, the p53-associated Cyp18 was probed by LC-ESI-MS/MS (data not shown), as well as by immunoblotting using a polyclonal antiserum against Cyp18 (Figure 1c ). Cyp18 associated with p53 independent of the p53 species expressed or of its subcellular distribution. Thus, wild-type p53 and mutant p53 interacted equally well with Cyp18. A characteristic feature of MCF-7 cells is the low amount of p53 in the cytosol compared with the other cell lines used in our study. Nevertheless, even these minor amounts interacted with Cyp18. On the other hand, antibodies unrelated to p53 or Cyp18 did not co-precipitate both proteins (data not shown).
Interaction between p53 and Cyp18 requires an active PPIase The observed physical interaction between p53 and Cyp18 might have been mediated by nucleic acids or other proteins. Therefore, precipitations with highly purified recombinant Cyp18 and p53 were performed. To reflect physiological conditions, a molar excess of Cyp18 (5.7 mM) over p53 (0.7 mM) was used. The anti-p53 antibody DO1 co-precipitated Cyp18 and an anti-Cyp18 antiserum reciprocally co-precipitated p53, as detected on immunoblots ( Figure 2a ) and MS analysis (Supplementary Figure 4 ). Control experiments ensured that DO1 did not crossreact with Cyp18 ( Supplementary  Figure 3) and the anti-Cyp18 antiserum did not crossreact with p53 (data not shown). Preincubation of Cyp18 with increasing concentrations of cyclosporine A (CsA), a tight binding active site inhibitor of Cyp18, led to a gradual reduction of complex formation with p53 ( Figure 2b ), indicating that the active site of Cyp18 was involved in p53 binding. To get further evidence for this conclusion, we tested the active site mutated Cyp18 variant Q62T (Fischer et al., 1984) . Again, 5.7 mM of Cyp18 Q62T was incubated with 0.7 mM p53, followed by CoIP using DO1. The Cyp18 Q62T variant was not able to co-precipitate p53, as revealed by sensitive MS analysis ( Figure 2c ).
Mapping of the p53 interaction site
An N-terminal p53-fragment of about 28 kDa was present in minor amounts in some p53 preparations that interacted with Cyp18 (data not shown). We, therefore, suspected a major binding site of Cyp18 in the p53-N-terminus. To confirm this putative interaction site, CoIPs using DO1 were performed from a mixture Figure 2 The active site of cyclophilin 18 (Cyp18) interacts with p53. (a) Immunoblot of mixed purified p53 and Cyp18 subjected to coimmunoprecipitation (CoIP) using an anti-Cyp18 serum or the anti-p53 antibody DO1, respectively. (b) Sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) showing p53-Cyp18 complex formation under the influence of different amounts of the Cyp18 inhibitor CsA (after 30-min preincubation). The precipitated proteins were separated by 12.5% SDS-PAGE and stained with Coomassie. The rectangles mark bands, in which p53 and Cyp18 were identified by MS. p53 was under the heavy chain of immunoglobulin gamma (IgH). A densitometric evaluation of the Cyp18 bands is also shown, in which the optical density in the absence of CsA was set to 100%. (c) SDS-PAGE of recombinant p53 mixed either with wild-type Cyp18 or with mutant Cyp18 Q62T and subjected to CoIPs using DO1. The resulting protein complexes were separated by SDS-PAGE followed by Coomassie staining.
The rectangles mark gel areas that were analysed by MS.
Cyclophilin 18-p53 interactions N Baum et al of 0.7 mM recombinant, full-length p53 and 0.7 mM GSTp53 1À81 , both added to 5.7 mM Cyp18. These experiments revealed that Cyp18 interacted with both full-length p53 and the first 81 N-terminal amino acids of p53 ( Figure 3a) . Taken together, these data strongly indicated that the main interaction site between both proteins was localized at the N-terminus of p53, an area harboring a proline-rich domain located within the amino acid residues 64-91. To further narrow down the suspected target site for Cyp18, a peptide spanning amino acids 68-81 of p53 (p53
68À81
, 5 0 -EAAPPVAPA-PAAPT-3 0 ) was synthesized. Preincubation of a 10-fold molar excess of this peptide considerably inhibited the interaction of Cyp18 with GST-p53 1À81 ( Figure 3b ). Moreover, the same peptide carrying an arginine at position 72 instead of a proline showed a much lower inhibitory capacity (data not shown), suggesting that the Pro71-Pro72 bond was responsible for the interaction with Cyp18. Interestingly, the Pro71-Pro72 bond of p53 represents a position that shows a naturally occurring polymorphism. To confirm whether this polymorphic site indeed was the target of Cyp18, we expressed fulllength p53 with either a proline or an arginine residue at codon 72 in the p53-null human lung carcinoma cell line H1299. In these cells p53 appears to be basically activated, as shown in the Supplementary Figure 5 and by Siddique and Sabapathy (2006) . Both p53 as well as Cyp18 were present in the cytoplasmic and nuclear protein fractions of the corresponding H1299(p53 72P ) and H1299(p53 72R ) cells ( Figure 3c ). Subsequent CoIPs revealed that Cyp18 bound equally well to p53 72P from the nuclear and cytoplasmic fractions of these cells ( Figure 3d ). In contrast, the interaction between Cyp18 and p53 72R was significantly decreased. Collectively, these data indicate that the proline-rich region is the major binding site for Cyp18.
Molecular modeling of the Cyp18-p53 interaction site Unexpectedly, there exists a striking sequence homology between the bound region of the HIV-1 capsid protein and the proline-rich part of p53 centered at Pro72 (Figure 4a ). Thus, a detailed assessment of substrate binding of Cyp18 can be obtained from the threedimensional structure of this PPIase bound to the N-terminus of the HIV-1 capsid protein (Gamble et al., 1996) . To assess the structural implications of ) and H1299(p53 72R ) by immunoblotting (input control). (d) The cyt and nuc protein fractions (panel c) were subjected to CoIPs using antibody DO1. The respective immunoblots were analysed using biot.DO1 and anti-Cyp18 antiserum. According to densitometric analysis of the protein bands, at least five times less Cyp18 was pulled down by p53 72R compared with p53 72P in the respective cyt and nuc protein fractions.
Cyclophilin 18-p53 interactions N Baum et al the proposed Cyp18-binding motif, modeling of the complex was performed using structural information available from the RCSB Protein Data Bank (1AK4, for details, see the Supplementary information). Molecular modeling revealed that the proline-rich motif of p53 fitted well into the active site of Cyp18 without sterical clashes (Figure 4a and b) . Substitution of the HIV-1 capsid protein residues Asp213, Gly221, Gln227 and Glu230 by the corresponding prolines found in p53 did not result in prohibitive van-der-Waals contacts. Of the prolines mentioned, only Pro71 (corresponding to Gly221 in the HIV-1 capsid protein) resided in the binding pocket, whereas all the other proline substitutions were solvent exposed and removed from the Cyp18 surface. In conclusion, biochemical data and structural considerations supported a direct p53-Cyp18 interaction that required the catalytic site of Cyp18 and that was most likely mediated by the proline-rich area centered at Pro71-Pro72 of human p53.
Cyp18 reduced the p53-DNA binding activity in vitro and CsA stimulates promoter activity of p53-dependent genes The intracellular content of Cyp18 is definitely higher than that of p53 (Harding et al., 1986; Ma et al., 2005) . To analyse whether Cyp18 modulated the sequencespecific DNA-binding activity of p53, electrophoretic mobility shift analysis assays were performed by using a molar excess of Cyp18 over p53. Preincubation of 69 nM p53 with 8.3 mM Cyp18 for 30 min resulted in a clearcut decrease in p53 binding to the DNA sequence derived from the human gadd45 gene (Figure 5a , lanes 3 and 5).
In contrast, preincubation of 69 nM p53 with 8.3 mM of the inactive Cyp18 Q62T variant did not influence the amount of the shifted p53-DNA complex (lanes 3 and 6). Supershift experiments using an anti-p53 antibody confirmed the specificity of p53-DNA binding (lane 4). These data indicate that Cyp18 substantially decreased the binding of p53 to its consensus DNA sequence. Treatment of H1299(p53
72P
) cells with CsA (500 nM) increased p53-reporter gene expression in a moderate but statistically significant (Student's t-test criteria) manner (Figure 5b ). In contrast, changes in reporter activities after treatment of H1299(p53 72R ) cells were statistically nonsignificant (data not shown).
p53-dependent apoptosis was enhanced in Cyp18-deficient Jurkat T cells To analyse the impact of Cyp18 on p53-dependent apoptosis, Cyp18-proficient (Cyp18 þ / þ ) and Cyp18-deficient (Cyp18 À/À ) Jurkat T cells were incubated for 6 h with different concentrations of daunorubicin. As a control, different concentrations of staurosporine were applied to Jurkat cells for 4 h, to induce p53-independent apoptosis. Cell lysates were applied to immunoblot analysis using an anti-caspase 3 antibody (Figure 6b and c). In Cyp18-deficient cells, an increased amount of cleaved caspase 3 compared with Cyp18-proficient cells indicated an increased apoptotic response to daunorubicin. In contrast, staurosporine induced apoptosis in both cell lines to a similar extent. Application of 2 mM daunorubicin caused a time-dependent induction of apoptosis in Cyp18-deficient cells as assessed by a timedependent processing of caspase 3. In Cyp18-deficient cells, processing was first detected after 2-h treatment with daunorubicin, whereas in Cyp18-proficient cells nearly no caspase 3 activation occurred over the whole time range examined (Figure 6d ). p53 was induced in Figure 4 Model of the interaction region of cyclophilin 18 (Cyp18) and p53. (a) The heavy atoms of Cyp18 (gray) and of the residues Glu68 to Pro75 of p53 (red/orange) are shown. For Cyp18 all residues within a 5 Å distance of an atom of the p53 stretch are included. The hydrogen bonds discussed are depicted in green: The carbonyl oxygen of Pro72 forms a bi-dentate hydrogen bond with both the N Z2 amino protons of the guanidine group in Arg55 of Cyp18. A further hydrogen bond establishes an interaction of the carbonyl oxygen of Ala70 to a side chain proton of the Gln63 amide. Finally, the amide proton of Ala70 in p53 can form a hydrogen bond to the carbonyl oxygen of Gly72. Thus, the stabilization network is very similar to that observed in the X-ray structure of the Cyp18-HIV-1 capsid protein complex, in which six hydrogen bonds including a bi-dentate hydrogen bond involving the N Z2 amino protons of Cyp18 are present. The insert shows the alignment of the proline-rich motif of p53 and the crystallized fragment of the HIV-1 capsid protein. Cyclophilin 18-p53 interactions N Baum et al both Cyp18-deficient and Cyp18-proficient cells after daunorubicin treatment. In Cyp18-deficient cells, the p53 pro-apoptotic target gene Fas showed an already significantly increased basal expression, whereas in Cyp18-proficient cells a significant Fas expression level could not be observed until the concentration was 10 mM daunorubicin ( Figure 6e) .
The percentage of apoptotic cells in Cyp18-proficient and Cyp18-deficient Jurkat cells induced by daunorubicin was determined by fluorescence-activated cell sorter annexin-V staining. In the absence of Cyp18, the daunorubicin-induced apoptosis was increased up to 51% compared with 13% apoptotic cells in Cyp18-proficient cells (Figure 6f ). Collectively, these data indicate that Cyp18 had an antiapototic effect in cells expressing p53. Interestingly, the protein expression level and localization of p53 are very similar in both Cyp18-proficient and Cyp18-deficient cells (Figure 6a and Supplementary Figure 7) .
Blockade of Cyp18-p53 interaction changes the cell cycle regulation in a p53 72R ). Importantly, the changes in the cell cycle distribution upon CsA treatment were most prominent in the H1299(p53 72P ) cell line. In this study, cells in the G2/M population increased from 15 to 44%, whereas those in the G1 population decreased from 57 to 30%. The observed increase of the G2/M population was statistically significant (Student's t-test criteria, data not shown), whereas the proportion of cells in S-phase was not significantly affected. The p53 and Cyp18 levels are shown in Figure 7c . As the absolute number of cells present in the cell samples for fluorescence-activated cell sorter analysis was not changed upon CsA treatment, these data indicate that the only change at position 72 from arginine to proline in an isogenic background markedly influenced the responsiveness of p53-positive cells to the Cyp18 inhibitor and immunosuppressant drug CsA in a cellular context.
Discussion
The tumor suppressor p53 is a multifunctional protein that regulates various cellular stress responses, most of which are mediated by protein-protein interactions. Initially, our experiments were designed to uncover the interaction partners of p53 under non-stress conditions, as 'non-activated' p53 might be involved in the prevention and repair of endogenous DNA damage (Albrechtsen et al., 1999) . About 200 potential interaction partners were identified in preliminary studies (data not shown). Among these were different chaperones, as well as the PPIases Cyp18, Cyp23 and FKBP25 (see Supplementary Table 1) . In this study, we focused on the p53-Cyp18 interaction, because of the cytoplasmic ) lines with the reporter gene constructs, cells were treated with CsA (500 nM) and cultivated for further 6 h at 32 1C. neg. control: mixture of a non-inducible firefly luciferase construct and constitutively expressing Renilla luciferase construct; p53-reporter: mixture of an inducible p53-response firefly luciferase and constitutively expressing Renilla luciferase construct; pos. control: mixture of constitutively expressing GFP, constitutively expressing firefly luciferase and constitutively expressing Renilla luciferase constructs. The results of five independent experiments are shown.
Cyclophilin 18-p53 interactions N Baum et al and nuclear localization of Cyp18 (Marks et al., 1991) and the fact that the cyclophilin inhibitor and frequently prescribed drug CsA was already shown to influence p53-mediated processes (Pyrzynska et al., 2002) . Complex formation between p53 and Cyp18 was observed within subcellular extracts and between purified recombinant proteins, indicating a direct physical contact between both proteins. This interaction emerged independently from the activation status of p53. The p53-Cyp18 interaction required the active site of Cyp18, because (i) a Cyp18-p53 complex was not formed in the presence of the Cyp18 inhibitor CsA and (ii) an active-site corrupted Cyp18 Q62T variant was not able to interact with p53. Moreover, the fact that Cyp18 inhibited the ability of p53 to bind to a p53-responsive promoter DNA strongly suggests that Cyp18 modulated -/-cells compared with Cyp18 þ / þ cells. Cells were treated with different concentrations of DR for 6 h, lyzed and separated via 15% SDS-PAGE for immunoblot analysis. Membranes were probed with an anti-Fas antibody, anti-Cyp18 rabbit antiserum or anti-p53 antibody DO-1 and re-probed with an anti-b-actin antibody. (f) Percentage of apoptotic cells after DR treatment determined by fluorescence-activated cell sorter (FACS) annexin-V staining. Cyp18-proficient and -deficient cells were incubated with or without 1 mM DR for 6 h. Cells were harvested, washed and resuspended in buffer with 50 mg/ml propidium iodide and annexin-V and subsequently analysed by flow cytometry. Experiments were conducted in triplicate; error bars represent s.d.
Cyclophilin 18-p53 interactions N Baum et al the conformational state of p53. This is in line with the observation that the functionally corrupted Cyp18 Q62T variant was not able to inhibit p53 binding to this DNA response element.
The only PPIase already known to interact with p53 is Pin1 . Apparently, with respect to promoter binding, Cyp18 and Pin1 behave antagonistically. The latter was reported to enhance the DNAbinding and transactivation potential of p53 (Zacchi et al., 2002; Zheng et al., 2002) , whereas Cyp18 decreased it. Interestingly, both Cyp18 and the Pin1 homologue Ess1 of Saccharomyces cerevisiae show opposing effects too, in which human Cyp18 increases and Ess1 decreases the disruption of gene silencing by the Sin3-Rpd3 histone deacetylase complex (Are´valo-Rodrı´guez et al., 2000) . In our assays, Pin1 was not detected as an interaction partner of p53, possibly because the Pin1-p53 interaction is part of the DNA damage response that was not induced in our experiments (with the exception of daunorubicin to provoke p53-dependent apoptosis, see below).
The sequence of p53 encompasses 45 amino acidproline bonds, all of which are potential targets for the PPIase activity of Cyp18 (Harrison and Stein, 1990) . Out of these, the binding site was narrowed down to the N-terminal part of human p53, because (i) the p53 fragment GST-p53 1À81 , representing the transactivation and proline-rich domain, was able to interact with Cyp18 to a similar extent as full-length p53, and (ii) the p53 64À81 , representing only a part of the proline-rich domain, was shown to inhibit the p53-Cyp18 interaction. These results were further confirmed by threedimensional structure modeling based on the existing HIV-1 capsid protein-Cyp18 crystal structure (Gamble et al., 1996) . The p53 64À81 fragment fitted in the binding site of Cyp18 similar to the HIV-1 capsid protein. The modeled structure contained proline-71 in the active site of Cyp18. Pro71 is next to the well-documented genetic p53 polymorphism encoding either an arginine or a proline at codon 72 (Matlashewski et al., 1987) . Substitution of a proline to an arginine at this position largely reduced but did not completely abolish Cyp18 binding. This was supported by our modeling studies showing that a proline-to-arginine substitution at this location will not necessarily compromise Cyp18 binding. In fact, the side chain of Pro72 (Figure 4a , pink residue, see also the Supplementary information) points to a cleft between two phenylalanine residues of Cyp18, which allow to accommodate the longer side chain of the Arg55 residue of Cyp18 without disturbing the bound p53 backbone. However, an attenuation of p53 binding can be expected when the charged and voluminous Arg72 has to be positioned between or near to Cyp18 ) and MCF-7 cells that endogenously express wild-type p53. The respective immunoblots were analysed using DO1 and anti-Cyp18 antiserum.
Cyclophilin 18-p53 interactions N Baum et al residues Arg55, Phe60, Met61, Gln63, Cys115, Thr119, Leu122 and His126. These theoretical considerations are in line with the experimental data showing that Cyp18 targeted the sequence next to Pro72 and that an arginine at this position decreased the interaction. A similar dependence of the interaction on proline-72 has also been described for members of the ASPP protein family that bind both p53 72P and p53 72R with different affinities and regulate p53 72P activity selectively (Bergamaschi et al., 2006) .
The two polymorphic forms of p53 are functionally not equivalent. The p53 72P variant was reported to activate transcription and DNA repair mechanisms efficiently (Thomas et al., 1999) , whereas the p53 72R variant is more efficient in inducing apoptosis (Dumont et al., 2003) . Hence, we tested whether the p53-Cyp18 interaction modulated the sensitivity of cells to apoptotic stimuli.
The p53 72R variant expressed in Jurkat cells (Lamb and Crawford, 1986) should be able to bind Cyp18, however, with a decreased efficiency. The level of p53-dependent apoptosis induced by daunorubicin (Johnson et al., 1999) was significantly higher in Cyp18-deficient Jurkat cells in which no complex formation between p53 and Cyp18 is possible. In contrast, p53-independent apoptosis induced by staurosporine was found to develop to the same level in Cyp18-positive and -negative Jurkat cells. These data suggest that binding of Cyp18 to p53 provides an antiapoptotic potential and are in line with our finding that the Cyp18-p53 interactions attenuated sequence-specific DNA binding of p53. The overexpression of Cyp18 in cancer cells of different origin (Rey et al., 1999; Choi et al., 2007) , as well as in patient tissue specimens (Howard et al., 2004) , supports this conclusion. Growth inhibition of lung cancer cell lines as a result of Cyp18 knockdown by RNA interference also emphasizes an antiapoptotic role of Cyp18 (Howard et al., 2005) .
Opposed in vivo effects of CsA were described. Procarcinogenic side effects were observed when CsA was used as an immunosuppressant in transplantation medicine. Patients treated with CsA develop tumors much more frequently than control probands that had been treated with, for example, rapamycin, and relations to p53 were considered (Jensen et al., 1999; Herman et al., 2001) . In contrast, CsA was found to have chemotherapeutic effects on a variety of cancer cells (Larsson et al., 1991; Ross et al., 1997) . We have found that CsA generated differential effects on the cell cycle distribution of cells harboring either the p53 72P or the p53 72R variant, and that these effects are at least partially p53-dependent. In order to minimize stress conditions, nanomolar concentrations of CsA insufficient to induce apoptosis were used (Pyrzynska et al., 2002) . The expression of the p53 72P variant in H1299 cells caused a significant accumulation of G2/M phase cells in the presence of CsA as compared with p53-negative cells and cells expressing the p53 72R variant. A p53-dependent G2/M arrest that involved repression of the transcription of cdc2 and cyclin B1 genes and probably also alterations of the intracellular transport of cyclin B1 protein was already shown (Taylor et al., 1999) . As CsA is a tight binding inhibitor of Cyp18, cellular application of CsA will likely release p53 from p53-Cyp18 complexes, which may be more dramatic for p53 72P than for p53 72R . In the absence of Cyp18, either induced genetically or after complex deterioration by the addition of CsA, p53 may attain an increased affinity toward its corresponding DNA recognition elements, which in turn might result in the observed emerging G2/M arrest and proapoptotic effects. The results of the p53-reporter assay are in support of this hypothesis: CsA treatment caused a significant increase in the respective p53-dependent promoter activities of H1299(p53 72P ) but not of H1299(p53 72R ) cells. Again, the two polymorphic forms of p53 were found to be functionally not equivalent.
In conclusion, our data provide the first evidence that Cyp18 is a p53 binding protein that affects the functions of this tumor suppressor in cell cycle regulation and apoptosis. These effects are more pronounced in human cells carrying the proline-72 variant of p53 rather than the arginine-72 form of p53. Therefore, it will be highly interesting to analyse whether the frequently described pro-and anticarcinogenic effects of CsA can be correlated to the respective status of p53 at this polymorphic site and with the potential modulation of the p53-Cyp18 interaction.
Materials and methods
Cell culture and treatment MCF-7 cells were cultured in RPMI medium (c.c.pro, Oberdorla, Germany) supplemented with 10% FCS (Sigma Aldrich Chemie GmbH, Munich, Germany). H1299 and stably transfected p53-positive H1299(p53 72P ) and H1299(p53 72R ) cells were derived as described in Siddique and Sabapathy (2006) . CCRF-CEM cells and mouse embryonal fibroblasts were grown in DMEM-medium (c.c.pro) supplemented with 10% FCS. Cyp18-deficient and proficient Jurkat cells were grown as described (Braaten and Luban, 2001 ).
Proteins and peptides
Recombinant p53 was prepared as described (Soe et al., 2002) . Recombinant wild-type Cyp18 and the Cyp18 Q62T variant were isolated as described (Fangha¨nel, 2003) . A p53-derived peptide spanning amino acids 68-82 (p53 68À82 ) was synthesized by D Imhof (University Jena, Germany). A fragment of human p53 comprising amino acids 1-82 fused to GST (GST-p53 1À81 ) was purchased from Jena Bioscience (Jena, Germany). The anti-p53 monoclonal antibody DO1 was purified from tissue culture supernatants. A biotinylated sample of DO1 (biot.DO1) was prepared according to the instructions of the manufacturer (Perbio Science Deutschland GmbH, Bonn, Germany). Peroxidase-conjugated avidin (Merck Chemicals, Darmstadt, Germany) was used together with biot.DO1. The anti-mousep53 monoclonal antibody Ab-3 and the interspecies anti-p53 sheep antibody Ab-7 were obtained from Merck Biosciences (Darmstadt, Germany). The anti-caspase 3 antibody was provided by Cell Signaling Technology (Danvers, MA, USA). The anti-Cyp18 rabbit antiserum was obtained from pab production (Herbertshausen, Germany). The anti-Fas antibody was purchased from Calbiochem (Darmstadt, Germany).
The anti-b-actin antibody was supplied by Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit anti-mouse, goat anti-rabbit and rabbit anti-sheep antibodies conjugated with horseradish peroxidase were purchased from Promega (Mannheim, Germany).
Preparation of subcellular protein fractions, coimmunoprecipitations and protein identification by LC-ESI-MS/MS analysis Cytoplasmic and nuclear protein fractions from different cell lines were prepared by using the NE-PER reagents (Thermo Scientific, Rockford, IL, USA). The efficiency of subcellular protein fractionation is shown in Figure 1 in the Supplementary information. CoIP experiments were performed according to Bauerschmidt et al. (2007) using Protein A-Sepharose 6MB (GE Healthcare, Munich, Germany). Proteins were identified by LC-ESI-MS/MS and/or immunoblotting. Tryptic in-gel protein digests, prepared according to Shevchenko et al. (1996) , were analysed with an LC-ESI-MS equipment consisting of an Ettan micro LC-HPLC (GE Healthcare) and a LTQ mass spectrometer (Thermo Scientific, Waltham, MA, USA). For protein identification the BioWorks 3.2 software (Thermo Scientific) and the NCBI human protein database were used.
Gel shift and p53 reporter assays For electrophoretic mobility shift analysis, the 'Gel-Shift Kit Nr. 7193' (Panomics Inc., Fremont, CA, USA) was used.
The cignal p53 reporter assay kit (SABiosciences, Frederick, MD, USA) was used according to the instructions of the manufacturer.
Fluorescence-activated cell sorter analysis Harvested cells were fixed in cold absolute ethanol for 1 h at 4 1C. Before analysis, fixed cells were washed twice with PBS and subsequently resuspended in PBS containing 250 mg/ml RNAse A (Qiagen, Hilden, Germany) and 40 mg/ml propidium iodide (Sigma-Aldrich, Taufkirchen, Germany) for 30 min at 37 1C in the dark. The propidium iodide fluorescence of individual cells was determined with an EPICS XL MCL flow cytometer (Beckman Coulter, Krefeld, Germany). For each measurement approximately 10 000 cells were analysed.
Conwflict of interest
The authors declare no conflict of interest.
